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Background: Chronic obstructive pulmonary disease (COPD) guidelines emphasize the impor-
tance of patient education to improve quality of life and avoid exacerbations. Longitudinal
evaluations of structured management of COPD in primary care are lacking.
Aim: To evaluate the impact of primary care asthma/COPD clinics on exacerbations, hospital-
izations, and associated costs in COPD.
Methods: This population-based, retrospective, observational study, linking primary care med-
ical records data to mandatory Swedish national registries, included patients with COPD from
76 primary healthcare centers (1999e2009). A questionnaire on access to an asthma/COPD
clinic was retrospectively answered. Propensity score matching was performed at index (COPD
diagnosis) by center type (with and without an asthma/COPD clinic). Poisson regression was
used to compare the yearly rate of exacerbations (hospitalization, emergency visits, or pre-
scription for oral steroids or antibiotics) and COPD-related prescriptions at the centers. An1 498510; fax: þ46 184 716675.
larna.se (K. Lisspers).
nhagen, Denmark.
4.06.002
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
nd/3.0/).
1346 K. Lisspers et al.economic analysis was performed from the Swedish healthcare perspective using 2011 unit
costs and the incremental cost-effectiveness ratio was calculated.
Results: The study included 21,361 patients (mean age, 68.0 years; 53% female). Access to
asthma/COPD clinics increased from 34% to 85% during the study period. Patients at primary
healthcare centers with asthma/COPD clinics had 27% fewer exacerbations (0.71 vs. 0.98)
and 37% fewer hospitalizations annually (0.36 vs. 0.58) (p < 0.0001). Asthma/COPD clinics
reduced the annual cost of medication and healthcare contacts by 37% (SEK 52,892 [V5858]
to SEK 33,410 [V3700] per patient).
Conclusions: Patients at primary healthcare centers with asthma/COPD clinics experienced
fewer COPD exacerbations and hospitalizations, and overall treatment costs were substantially
reduced.
ClinicalTrials.gov identifier: NCT01146392.
ª 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Due to exposure to risk factors and an ageing population,
the prevalence of chronic obstructive pulmonary disease
(COPD) is increasing worldwide. [1] The disease is an
important challenge for public health and healthcare sys-
tems [2], imposing substantial healthcare and societal costs
[1]. Many patients remain undiagnosed, and many diag-
nosed patients are not treated in accordance with inter-
national guidelines [3]. Current guidelines emphasize the
importance of patient education to improve disease
knowledge and eliminate risk factors, and also provide
recommendations for treatment options with the overall
goal of improving quality of life and reducing exacerba-
tions. If left untreated or inadequately treated, exacerba-
tions and poor quality of life contribute to a permanent
deterioration in health status and drive costs [1,4]. To face
these challenges, there is a need for an efficient and pro-
active primary healthcare structure to enable optimal
management and symptom relief [5e7].
The Swedish healthcare system is organized into primary
healthcare centers, each responsible for a defined popu-
lation. With primary care as the base for patient health-
care, structured COPD management in an asthma/COPD
clinic, integrated at the primary healthcare center, facili-
tates routine diagnosis, education about the disease and
regular follow-up. The main criteria for an asthma/COPD
clinic are that it should be led by a disease-specialist pri-
mary care nurse, who works part-time at the clinic, and
have a specifically appointed general practitioner as the
responsible physician. The main tasks of the asthma/COPD
nurse are to perform diagnostic lung function tests, offer
smoking cessation programs, support patient education and
self-management but also follow-up, especially of patients
with poor disease control [8]. However, every general
practitioner is responsible for the management, i.e diag-
nosis, treatment and follow-up of his/her patients with
COPD, often in cooperation with the nurse. In addition, the
general practitioner always has the opportunity to refer to
a pulmonologist/respiratory specialist if there is a need of
care that is not available at the primary healthcare center,
or if the general practitioner is uncertain of the diagnosis or
treatment. There are no limits regarding referrals. Manypatients, especially with severe COPD, are managed in
collaboration with the general practitioner and pulmonol-
ogist/respiratory specialist.
During the past 15 years, these integrated nurse-based
asthma/COPD clinics have gradually developed in primary
care in response to increasing patient demands, and in
concordance with established national criteria [8,9]. In a
survey conducted in western Sweden, 80% of primary health-
care centers reported having an asthma/COPD clinic on site.
[10]However, there is a lackof knowledgeof theeffectiveness
of asthma/COPD clinics, and well-designed studies are scarce
[11]. In one Swedish study, the frequency of acute exacerba-
tions was lower for patients with COPD managed at primary
healthcare centers with an asthma/COPD nurse [12], and
another showed that quality of carewas dependent upon time
allocated for the nurseepatient interaction [13].
Asthma/COPDclinics inprimarycare, including trainingand
employment of specialized nurses, may represent an addi-
tional cost to the healthcare system.Costsmay also increase if
better-structured care leads to increased resource utilization
with respect to maintenance pharmacological treatment.
Conversely, costs may decrease if improved maintenance
therapy and patient management reduces the rate of exac-
erbations and the need for costly acute treatments. There is a
lack of data evaluating asthma/COPD clinics and educational
programs in primary care, particularly with regard to health-
economic outcomes in patients with COPD [11,14].
This is the first large, retrospective, epidemiological
study that links data from medical records and mandatory
national healthcare registers in patients with COPD. The
aim was to describe the development of COPD healthcare
structure in primary care and evaluate the effectiveness of
asthma/COPD clinics in primary care, with respect to pa-
tient exacerbations, hospitalizations, resource utilization,
and treatment costs.Materials and methods
Study design
The population-based, retrospective, observational PATHOS
study was conducted by linking data from primary care
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Swedish national registries from 1999 to 2009. The linkage
of data was performed by the Swedish National Board of
Health and Welfare, and the database was managed by the
Department of Public Health and Caring Sciences, Uppsala
University, Uppsala, Sweden. The personal identification
number used to identify patients with respect to all con-
tacts with healthcare professionals was replaced by a study
identification number prior to further data processing.
The study protocol was approved by the regional ethics
committee in Uppsala, Sweden (reference number 2010/040)
and registered at www.clinicaltrials.gov (NCT01146392). The
AstraZeneca study code was NIS-RSE-DUM-2010/1. Several
analyses of data from this study have previously been pub-
lished [15e17].
Study population
The baseline population included patients with physician-
diagnosed COPD (J44, according to the International Clas-
sification of Diseases, 10th Revision, Clinical Modification
[ICD-10-CM]). The index date was defined as the date of
first COPD diagnosis. Starting from 1 January 1999, patients
were followed to 31 December 2009, emigration, or death.
Patients eligible for matching were classified according to
the type of center at index (with asthma/COPD clinic vs.
without asthma/COPD clinic). No exclusion criteria were
predefined.
Primary healthcare centers
No formal stratification of primary healthcare centers was
performed, but effort was made to ensure that the
included centers covered a representative sample of rural
and urban areas, public and private providers, and center
size. A total of 76 centers were included, with a catchment
area of w800,000 individuals corresponding to 8% of the
Swedish population.
Access to an asthma/COPD clinic was defined as avail-
ability of a disease-specialist primary care nurse.
Data sources
Data from primary care electronic medical records (e.g.
date of birth, sex, diagnoses [ICD-10-CM], number of con-
tacts, lung function assessments, and drug prescriptions)
were extracted using an established software system
(Pygargus Customized eXtraction Program, CXP; Pygargus
AB, Stockholm, Sweden) [18]. Data were also extracted
from mandatory Swedish national registries: the National
Patient Register (inpatient hospital care [admission and
discharge dates, diagnoses] and outpatient hospital care
[contacts, diagnoses]), the Cause of Death register (date
and cause[s] of death), and the Swedish Prescribed Drug
Register.
In 2010, all primary healthcare centers in the study
responded to a questionnaire regarding the number of lis-
ted patients and the structure of the center during the
study period. Questions focused on access to an asthma/
COPD nurse, responsible general practitioner, spirometry,
and smoking cessation programs. Centers were classifiedaccording to the availability of an asthma/COPD nurse. If
unknown, centers were classified as having no asthma/
COPD nurse. Each center with an asthma/COPD nurse re-
ported the number of allocated nurse-hours per week per
1000 listed patients for 2009.
Outcome measures and variable definitions
COPD exacerbation definition
Exacerbations were defined as COPD-related hospitaliza-
tions (ICD-10-CM code J44 as primary diagnosis or J44.0/
J44.1 as secondary diagnosis), emergency visits (ICD-10
J44.0/J44.1 in outpatient hospital care), collection of oral
steroids (Anatomical Therapeutic Classification [ATC] Sys-
tem code H02AB) or antibiotics (ATC codes J01AA, J01CA).
Exacerbations occurring within 14 days were defined as a
single event.
Prescription event
Dispensed prescriptions of inhaled drugs used in obstructive
pulmonary diseases were defined using ATC codes: inhaled
corticosteroids (ICS; R03BA), long-acting b2-agonists
(LABAs; R03AC12 and R03AC13), short-acting b2-agonists
(SABAs; R03AC), tiotropium bromide (R03BB04), ipra-
tropium bromide (R03BB01), and fixed ICS/LABA combina-
tions (R03AK06 and R03AK07).
Medication utilization
Drug usage after index was calculated for each year for all
eligible patients in a given year. The end date of drug usage
was calculated from the prescribed dose.
Contacts
Defined as any patient visit, telephone contact, or pre-
scription contact.
Referrals
Defined as any referral to specialist care (out-patient hos-
pital visit) independent of type and reason.
Comorbidities
Diagnosed comorbidities were classified according to ICD-
10-CM.
Health-economic analysis
The economic analysis was based on the clinical outcomes
for the matched patient populations, and the annual cost
per patient for each of the two center types was calcu-
lated. The incremental cost-effectiveness ratio was
calculated by dividing the difference in costs between the
two types of centers with the difference in effect, to
determine the additional cost per exacerbation avoided by
having an asthma/COPD clinic compared with no clinic. The
analysis took a Swedish healthcare perspective and did not
consider productivity losses or other indirect costs. Direct
costs included general practitioner and nurse contacts,
hospitalizations, emergency visits, and exacerbation- and
COPD-related medication. The mean annual cost of treat-
ment was calculated by applying Swedish unit costs to the
estimated average annual resource use per patient. All unit
1348 K. Lisspers et al.costs were 2011 values, except medication costs, which
were collected in 2012 and were not indexed. Costs were
not discounted due to the 1-year time horizon of the
analysis.
The cost of a hospitalization day was based on Diagnose
Related Group (DRG) data (average cost per hospitalization
day for DRG 088, diagnosis J44.0e44.1) [19]. The costs of
emergency and specialist visits were based on the official
price list [20]. Costs of general practitioner and nurse
contacts were estimated from official cost databases
[21,22]. Pharmaceutical costs were based on the official
pharmacy retail price [23] of the most frequent prescrip-
tion for each type of therapy (including any patient co-
payment, excluding value-added tax, and parallel im-
ports). Costs were converted to Euros (V) using the average
2011 exchange rate [24].
Statistical analysis
The yearly rate of healthcare utilization events (exacer-
bations or prescriptions) was calculated using Poisson
regression with “events” as the dependent variable and
“time on center type” (with or without asthma/COPD
clinic) as the offset variable. If a center changed from not
having an asthma/COPD clinic, or vice versa, the patient
was regarded as having switched from one center type to
the other. Robustness analysis included the calendar year
at index date as a covariate in the Poisson regression.
Propensity score matching was used to compensate
concerns related to the non-random assignment of patients
to centers with or without an asthma/COPD clinic [25],
reducing potential confounding caused by unbalanced
covariates [26]. Patients belonging to either center type
were pair-wise matched (1:1), with propensity scores
calculated using a number of criteria during the 2 years
prior to and at the index date including: age; sex; available
lung function measurements; number of prescriptions for
antibiotics, oral steroids, tiotropium, ipratropium, ICS,
SABAs, LABAs, angiotensin receptor blockers, b-blockers,
statins, calcium antagonists, and thiazides; diagnosis of
diabetes, asthma, cancer, rheumatoid arthritis, heart fail-
ure, hypertension, and stroke; and number of previous
hospitalizations.
Results are mean values (standard deviation [SD]), un-
less otherwise stated. Data management and statistical
analyses were performed using SAS version 9.2 (SAS Insti-
tute Inc, Cary, NC, USA).
Results
Patient population and healthcare structure
Overall, 21,361 patients with a recorded COPD diagnosis
were identified at 76 primary healthcare centers, and
formed the study baseline population (Table 1). Of these,
53% were female, the mean age was 68.0 years, and 57%
were smokers (smoking status was available for one-third of
the study population).
The availability of asthma/COPD clinics increased during
the 11-year study period from 34% in 1999 to 85% in 2009
(Fig. 1). In 2009, 89% of the centers with asthma/COPDclinics reported that a nurse was available for 0.95 (0.70)
hours per week per 1000 listed patients. The availability of
the responsible asthma/COPD general practitioner
increased during the study period from 32% in 1999 to 80% in
2009. Likewise, the availability of spirometers and smoking
cessation programs increased from 41% and 24% in 1999 to
93% and 80% in 2009, respectively (Fig. 1).
Before matching, 11,846 patients were managed at pri-
mary healthcare centers with an asthma/COPD clinic at the
time of diagnosis, and the remaining 9515 patients were
managed at centerswithout an asthma/COPDclinic (Table 1).
Complete lung function data at index were available
from only one county and a limited number of patients:
15.2% (n Z 1800) at primary healthcare centers with an
asthma/COPD clinic and 7.5% (nZ 717) without an asthma/
COPD clinic. Post-bronchodilator forced expiratory volume
in 1 s/forced vital capacity-ratio was similar in the two
groups (Table 1).
All 21,361 patients were eligible for matching. Prior to
matching, the two populations (with or without an asthma/
COPD clinic) differed somewhat (Table 1). Following 1:1 pair-
wise propensity scorematching, two cohorts of 8202 patients
eachwere obtained. The cohortswere similar on themajority
of variables examined, but differed with respect to all
inhaled therapies with the exception of SABAs (Table 1).
Patients attending a primary healthcare center with an
asthma/COPD clinic had both significantly fewer total
physician contacts (8.12 [3.35] vs. 16.0 [10.7] per patient/
year; mean [SD]) and fewer referrals to specialist care (1.37
[0.51] vs. 1.98 [1.44] per patient/year) (Fig. 2). Patients
attending primary healthcare centers with an asthma/
COPD clinic were younger at COPD diagnosis than patients
at centers without an asthma/COPD clinic (67.4 [11.4] vs.
68.7 [11.2] years, respectively).
Exacerbation-related outcomes
Significant differences between the two propensity score-
matched populations were observed with respect to the
mean yearly rate of exacerbations and related outcomes
(Table 2). Patients managed at primary healthcare centers
with an asthma/COPD clinic experienced fewer COPD ex-
acerbations and hospitalizations annually than patients
managed at centers without an asthma/COPD clinic (0.71
vs. 0.98, and 0.36 vs. 0.58; 27% and 37% difference, number
needed to treat 3.7 and 4.7 respectively; p < 0.0001). In
addition, the number of days per year spent in the hospital
due to COPD was 35% lower for patients attending a center
with an asthma/COPD clinic than those without a clinic
(2.40 vs. 3.71 days, respectively; p < 0.0001). The yearly
number of emergency visits and collections of prescribed
antibiotics showed a similar difference (Table 2), whereas
prescription of oral steroids did not differ between the
groups (p Z 0.817). These results were unchanged after
applying the calendar year as a covariate.
Health-economic analysis
The total annual cost per patient was SEK 33,902 (V3754)
and SEK 53,546 (V5930) for primary healthcare centers with
and without an asthma/COPD clinic, respectively (Table 3).
Table 1 Baseline characteristics (matched and unmatched) 2 years preceding COPD diagnosis (index date) by centre type
(with and without asthma/COPD clinic).
Variable Unmatched Matched
PHCC with
clinic
n Z 9515
PHCC without
clinic
n Z 11,846
p-Value PHCC with
clinic
n Z 8202
PHCC without
clinic
n Z 8202
p-Value
Age at diagnosis, mean years (SD)a 67.4 (11.4) 68.7 (11.2) <0.0001 68.0 (11.3) 68.0 (11.6) 0.9598
Female genderb 6302 (53) 4945 (52) 0.0738 4325 (53) 4301 (52) 0.7075
BMI before index date, mean kg/m2 (SD)a,c 27.9 (5.8) 28.4 (6.2) 0.0249 28.3 (6.1) 27.9 (5.9) 0.0742
Smokersb,c 2982 (56) 986 (60) 0.0049 943 (60) 1813 (56) 0.0275
Exacerbationb 8609 (73) 6417 (67) <0.0001 5630 (69) 5612 (68) 0.7622
Oral steroids, prescriptions/yeara 4364 (37) 2870 (30) <0.0001 2791 (34) 2744 (33) 0.4377
Antibiotics, prescriptions/yeara 7164 (60) 4476 (47) <0.0001 4375 (53) 4475 (55) 0.1173
SABA, prescriptions/yeara 1117 (9.4) 537 (5.6) <0.0001 4215 (51) 4098 (50) 0.0677
LABA, prescriptions/yeara 2195 (19) 1837 (19) 0.1493 1693 (21) 1470 (18) <0.0001
ICS, prescriptions/yeara 4212 (36) 3395 (36) 0.8506 3148 (38) 2836 (35) <0.0001
Tiotropium, prescriptions/yeara 2023 (21) 3592 (30) <0.0001 1926 (23) 2191 (27) <0.0001
Ipratropium, prescriptions/yeara 3023 (32) 3111 (26) <0.0001 2720 (33) 2215 (27) <0.0001
Fixed ICS/LABA combination,
prescriptions/yeara
2322 (24) 4027 (34) <0.0001 2208 (27) 2560 (31) <0.0001
Post-bronchodilator FEV1,
z
mean % predicted normal (SD)a
63.4 (18.9) 58.9 (19.2) <0.0001 59.1 (19.1) 60.0 (19.8) 0.3832
Post-bronchodilator FEV1/FVC,
z
mean % (SD)a
63.4 (13.0) 62.7 (14.4) 0.2294 62.8 (14.4) 61.4 (13.4) 0.0620
Presence of co morbidities
Asthmab 2999 (25) 2428 (26) 0.737 2087 (25) 2083 (25) 0.943
Diabetesb 1625 (14) 1176 (12) 0.003 992 (12) 984 (12) 0.848
Cancerb 1724 (15) 1311 (14) 0.107 1139 (14) 1181 (14) 0.347
Heart failureb 2014 (17) 1995 (21) <0.001 1517 (18) 1538 (19) 0.674
Angina pectorisb 1585 (13) 1338 (14) 0.149 1086 (13) 1074 (13) 0.782
Myocardial infarctionb 969 (8.2) 761 (8) 0.628 619 (7.5) 614 (7.5) 0.882
Hypertensionb 4672 (39) 2833 (30) <0.001 2603 (32) 2747 (33) 0.017
Strokeb 1213 (10) 891 (9.4) 0.033 765 (9.3) 802 (9.8) 0.326
Data are presented as n (%), unless otherwise stated.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity;
ICS, inhaled corticosteroid; LABA, long-acting b2-agonist; OCS, oral corticosteroid; PHCC; primary healthcare centre; SABA, short-acting
b2-agonist; SD, standard deviation.
a T-test for unmatched and paired t-test for matched patients.
b Chi-squared and McNemar tests.
c Data available from a limited number of patients according to; BMI, unmatched 3744 patients, matched 2338 patients; smoking
status, unmatched 7004 patients, matched 4792 patients; spirometry, FEV1, unmatched 2704 patients, matched 1556 patients; FEV1/FVC
unmatched 2517 patients, matched 1467 patients.
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reduction in both the annual cost of medication and the
cost of healthcare contacts (Fig. 3). The total annual cost
per patient was reduced by SEK 19,644 (V2175) in centers
with an asthma/COPD clinic compared with centers without
a clinic. As patients at primary healthcare centers with an
asthma/COPD clinic experienced fewer exacerbations
(Table 2), the presence of such a clinic was the dominant
treatment strategy from a cost-effectiveness perspective
(i.e. more effective at lower costs).
Discussion
Main findings
This large, retrospective, propensity score-matched cohort
study evaluated the effectiveness of COPD management inprimary care, and demonstrated that patients managed at
primary care centers with nurse-based asthma/COPD clinics
experienced fewer COPD-related exacerbations and hospi-
talizations. Moreover, structured management of patients
with COPD increased in Sweden during the 11-year study
period, and access to asthma/COPD clinics at primary
healthcare centers considerably reduced treatment costs.
The fact that fewer referrals to secondary care and
fewer events were observed in patients managed at centers
with an asthma/COPD clinic may reflect a higher quality of
care and generally better organisation at centers with
structured COPD management.
Strengths and limitations of this study
This study has several important strengths, not least the
primary care setting, with no restrictions with respect to
Figure 1 Availability of trained asthma/COPD nurse, responsible asthma/COPD general practitioner, spirometry, and smoking
cessation programs during the study period 1999 to 2009. COPD: chronic obstructive pulmonary disease.
1350 K. Lisspers et al.age, medication use, comorbidities, or healthcare insur-
ance. This unbiased data extraction from electronic medi-
cal records linked to mandatory national healthcare
registers provides high-quality coverage and the opportu-
nity to follow a patient’s management over time using
personal identification numbers. The real-world design and
large population studied provide data that are increasingly
more demanded in respiratory disease research and have a
high level of applicability to the general population [27,28].
Propensity score matching ensured that all patients were
matched on a number of parameters to minimize bias and
the influence of confounding factors. The differences found
following matching likely reflects a difference in the overall
quality of care, better patient management, and treatment
with inhaled therapies at well-organized centers.
Further, possible unknown confounding factors may still
reside in the data. The completeness and accuracy of the
COPD diagnoses could not be fully verified by spirometry in
all cases, due to lack of structured reporting in medical
records. This does not mean that spirometry was not per-
formed when establishing the COPD diagnosis. Further-
more, characterization of primary healthcare centers by
the presence or absence of an asthma/COPD clinic was
performed retrospectively and may be subject to recall
bias. Other limitations were lack of available information
on the educational level of the nurse in the respiratory field
or the specific management used at the asthma/COPD
clinics, and smoking status for all included patients.
Interpretation of findings in relation to previously
published work
The main findings of this study support those of other
studies [12,29,30]. However, research evaluating different
management programs for COPD has yielded conflictingresults. Integrated disease management improved quality
of life for patients with COPD in primary care compared
with standard care [31], as did an action plan that included
the ongoing support of a case manager, which decreased
the impact of exacerbations on health status [32].
Conversely, other studies that compared a variety of man-
agement programs with standard care found no difference
in quality of life, efficacy, hospitalization, or death rates
between groups [33e35]. Nevertheless, there are few large
studies evaluating the association between asthma/COPD
clinics in primary care and exacerbations, hospitalizations,
and treatment costs.
One of the reasons for the positive effects in this study
could be that centers with well-organized COPD care
generally provide a higher quality of care. One indicator of
this is that the primary healthcare centers with an asthma/
COPD clinic had fewer referrals to secondary care for any
reason, as well as fewer all-cause physician contacts,
implying a more structured form of patient care. The earlier
diagnosis of COPD at primary healthcare centers with an
asthma/COPD clinic also reflects improved patient man-
agement, and is of importance for disease prognosis [36].
The health-economic analysis showed that overall
treatment costs were reduced for patients with COPD
treated at a primary healthcare center with an asthma/
COPD clinic, which is consistent with previous findings [37].
Ideally, such analyses should include all costs and effects
related to treatment. Investments to improve diagnosis
were not taken into account in the present study. Moreover,
the cost of training of nurses should also be considered.
However, given the substantial savings per patient per year,
it is likely that such investments would be recouped quickly.
The effect of improved care on quality of life, if included in
the study, would likely have added to the demonstrated cost
effectiveness of the asthma/COPD clinics.
Figure 2 Number of yearly A) physician contacts and B) referrals independent of cause divided by primary healthcare center
structure (with or without asthma/COPD clinic). COPD: chronic obstructive pulmonary disease.
Impact of asthma/COPD clinics on the management of COPD 1351Implications for future research, policy and
practice
Data from observational studies of propensity score-
matched cohorts provide an alternative to minimize bias
and confounding when randomization is not possible,
providing complimentary real-life data and alleviating some
of the limitations of controlled clinical trials [38]. This
study highlights the importance of structured care to
improve patient management, clinical outcomes, andreduce treatment costs associated with COPD care.
Furthermore, there is a need for more primary care studies
to determine asthma/COPD clinic parameters that influ-
ence patient outcomes and related costs.
Conclusions
In summary, this observational study linking primary care
records to mandatory national registries demonstrates that
primary healthcare centers with an asthma/COPD clinic
Table 2 Yearly occurrence of events among pairwise (1:1) propensity score-matched populations of COPD patients treated at
primary healthcare centres with or without asthma/COPD clinic, yearly rate of events and yearly number of days.
Variable PHCC with clinic PHCC without clinic Rate ratio (95% CI) p-Value
Exacerbations 0.71 (0.69, 0.73) 0.98 (0.95, 1.01) 0.74 (0.70, 0.75) <0.0001
Oral steroid prescriptions 0.82 (0.78, 0.86) 0.81 (0.77, 0.86) 1.01 (0.94, 1.08) 0.8107
Hospitalisations 0.36 (0.35, 0.38) 0.58 (0.55, 0.60) 0.63 (0.59, 0.67) <0.0001
Number of days at hospital 2.40 (2.26, 2.54) 3.71 (3.49, 3.94) 0.65 (0.60, 0.70) <0.0001
Antibiotic prescriptions 0.38 (0.37, 0.39) 0.52 (0.50, 0.54) 0.74 (0.71, 0.77) <0.0001
Emergency visits 0.18 (0.17, 0.19) 0.26 (0.24, 0.29) 0.68 (0.61, 0.76) <0.0001
CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting b2-agonist; OCS,
oral corticosteroids; PHCC; primary healthcare centre; SABA, short-acting b2-agonist.
Table 3 Unit costs (SEK 2011) and yearly cost per patient per year in centres with or without asthma/COPD clinic and ICER per
exacerbation avoided per patient per year among patients with COPD.
Resource Unit cost (SEK) PHCC with clinic PHCC without clinic Difference
Contact costs
Hospitalisation, days 5978 14,347 22,178 7831
Emergency, visits 2567 462 667 205
Non-emergency outpatient visits 3243 492 654 162
General practitioner, consultations 1254 10,182 20,064 9881
Nurse, consultations 459 2911 4422 1511
Total contact costs 28,394 47,984 19,590
Total contact costs, V 3144 5314 2169
Prescription costs
Fixed ICS/LABA combination prescriptions 1802 2414 2252 162
Tiotropium prescriptions 1243 1702 1653 50
LABA prescriptions 755 506 589 83
Ipratropium prescriptions 182 149 176 27
SABA prescriptions 161 197 236 39
Total medication costs 5508 5562 54
Total medication costs, V 610 616 6
Total costs 33,902 53,546 L19,644
Total costs, V 3754 5930 L2175
ICER Dominant
Data are presented as yearly costs per patient in SEK, unless otherwise stated.
COPD, chronic obstructive pulmonary disease; ICER, incremental cost-effectiveness ratio; ICS, inhaled corticosteroids; LABA, long acting
b2-agonist; PHCC; primary healthcare centre; SABA, short-acting b2-agonist.
Figure 3 Yearly treatment costs per patient in primary healthcare centers with and without an asthma/COPD clinic. COPD:
chronic obstructive pulmonary disease.
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overall cost of care, emphasizing the importance of access
to structured COPD care.
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